Poseida Therapeutics Inc
Poseida Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company's development candidates for Heme Malignancies includes P-BCMA-ALLO1, which is in Phase I trial to treat patients with relapsed/refractory multiple myeloma; P-CD19CD20-ALLO1, which is in Phase I trial for treating B cell malignancies an… Read more
Poseida Therapeutics Inc (PSTX) - Total Assets
Latest total assets as of September 2024: $293.58 Million USD
Based on the latest financial reports, Poseida Therapeutics Inc (PSTX) holds total assets worth $293.58 Million USD as of September 2024.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Poseida Therapeutics Inc - Total Assets Trend (2017–2023)
This chart illustrates how Poseida Therapeutics Inc’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Poseida Therapeutics Inc - Asset Composition Analysis
Current Asset Composition (December 2023)
Poseida Therapeutics Inc's total assets of $293.58 Million consist of 82.7% current assets and 17.3% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 16.2% |
| Accounts Receivable | $9.01 Million | 3.3% |
| Inventory | $1.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $1.32 Million | 0.5% |
| Goodwill | $4.23 Million | 1.5% |
Asset Composition Trend (2017–2023)
This chart illustrates how Poseida Therapeutics Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Poseida Therapeutics Inc's current assets represent 82.7% of total assets in 2023, an increase from 62.2% in 2017.
- Cash Position: Cash and equivalents constituted 16.2% of total assets in 2023, down from 61.4% in 2017.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 1.0% of total assets, a decrease from 26.0% in 2017.
- Asset Diversification: The largest asset category is accounts receivable at 3.3% of total assets.
Poseida Therapeutics Inc Competitors by Total Assets
Key competitors of Poseida Therapeutics Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
USA | $2.22 Billion |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $7.59 Billion |
|
ESSA Pharma Inc
NASDAQ:EPIX
|
USA | $110.50 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
Poseida Therapeutics Inc - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Poseida Therapeutics Inc generates 0.24x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Poseida Therapeutics Inc is currently not profitable relative to its asset base.
Poseida Therapeutics Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.20 | 3.28 | 5.82 |
| Quick Ratio | 3.20 | 3.28 | 5.82 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $172.44 Million | $ 175.69 Million | $ 105.32 Million |
Poseida Therapeutics Inc - Advanced Valuation Insights
This section examines the relationship between Poseida Therapeutics Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 10.62 |
| Latest Market Cap to Assets Ratio | 2.24 |
| Asset Growth Rate (YoY) | -22.2% |
| Total Assets | $273.88 Million |
| Market Capitalization | $614.61 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Poseida Therapeutics Inc's assets at a significant premium ( 2.24x), suggesting investors see substantial growth potential or unique competitive advantages.
Significant Asset Reduction: Poseida Therapeutics Inc's assets decreased by 22.2% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Poseida Therapeutics Inc (2017–2023)
The table below shows the annual total assets of Poseida Therapeutics Inc from 2017 to 2023.
| Year | Total Assets | Change |
|---|---|---|
| 2023-12-31 | $273.88 Million | -22.16% |
| 2022-12-31 | $351.84 Million | +30.64% |
| 2021-12-31 | $269.31 Million | -27.50% |
| 2020-12-31 | $371.48 Million | +152.72% |
| 2019-12-31 | $147.00 Million | +225.79% |
| 2018-12-31 | $45.12 Million | +77.26% |
| 2017-12-31 | $25.45 Million | -- |